Trial Profile

A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled, Randomized, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Parenterally Administered Suspension of Investigational Capsid Inhibitors in Healthy Adults

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VH 4004280 (Primary) ; VH 4004280 (Primary) ; VH 4011499 (Primary) ; VH 4011499 (Primary)
Indications HIV infections
Focus Adverse reactions; Pharmacokinetics
Sponsors ViiV Healthcare

23 Apr 2025 The number of arms has been change from 3 to 5.Addition of 7 new Primary end-points .no.of patients have been increased.
23 Apr 2025 Planned number of patients changed from 160 to 208.
23 Apr 2025 Planned End Date changed from 5 May 2026 to 2 Sep 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com